Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· December 17, 2025

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery

View original at finance.yahoo.com

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery First and only immunotherapy plus ADC regimen, used perioperatively, to exten…

Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

The KEYNOTE-B15/EV-304 trial results represent a potential advancement for cisplatin-eligible patients with muscle-invasive bladder cancer
80% confidence
The KEYNOTE-B15/EV-304 trial results are encouraging as nearly 50% of patients treated with standard neoadjuvant cisplatin-based chemotherapy and surgery experience recurrence
80% confidence

Data points we hold from this source

Merck & Co., Inc. · clinical trials	1600 trials
Merck & Co., Inc. · registrational studies	30 studies